Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

UniQure said it has aligned with the FDA on components of a statistical analysis plan for a registrational trial of AMT-130.

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.